VLP Therapeutics LLC

AAVogen Inc, based in Rockville, MD, is a pioneering biotechnology company specializing in gene therapy for muscle wasting diseases. With a focus on inclusion body myositis, Duchenne muscular dystrophy, and cancer cachexia, AAVogen's AVGN7 gene therapy has shown promising results in pre-clinical studies, effectively stabilizing muscle structure, increasing muscle mass and strength, and preventing muscle wasting. Driven by a personal mission, AAVogen was founded by a family directly affected by three muscle wasting diseases, fueling their unwavering commitment to developing safer and more effective therapies. AVGN7 has demonstrated its efficacy in various animal models, restoring muscle mass and strength even after wasting has occurred, and it can be administered directly into muscles or systemically. AAVogen also emphasizes patient outreach and education, providing support and information to individuals battling muscle wasting diseases.Generated from the website